Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application 2026

The fifth Advances in Malignant Lymphoma: From Discovery to Clinical Impact conference, held in cooperation with the International Conference on Malignant Lymphoma (ICML), will convene experts from academia, industry, government, and foundations to examine how molecular mechanisms and translational research are driving therapeutic progress. The program will highlight advances in understanding germinal center biology and beyond, lymphoma origins and classifications, including rare and aggressive subtypes, and microenvironmental influences, that define disease behavior and therapeutic response. This conference is uniquely positioned to integrate scientific discoveries across epigenetics, disease modeling, and computational biology with emerging therapeutic advances in antibody evolution, next-generation clinical assessment, degraders, and cellular therapies. Together, these efforts will capture the entire spectrum of lymphoma research and drive progress toward improved patient outcomes.